8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline profile

8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline: primaquine metabolite in rats; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	127542
CHEBI ID	165855
SCHEMBL ID	5644378
MeSH ID	M0107897

Synonym
carboxyprimaquine
77229-68-6
4-[(6-methoxyquinolin-8-yl)amino]pentanoic acid
CHEBI:165855
4-((6-methoxyquinolin-8-yl)amino)pentanoic acid
AKOS015940349
8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline
nzz7g26xiv ,
pentanoic acid, 4-((6-methoxy-8-quinolinyl)amino)-
unii-nzz7g26xiv
cmpamoq
SCHEMBL5644378
4-[(6-methoxy-8-quinolinyl)amino]pentanoic acid #
KIMKJIXTIWKABF-UHFFFAOYSA-N
4-[(6-methoxy-8-quinolinyl)amino]pentanoic acid
AC-27752
4-[(6-methoxy-8-quinolyl)amino]valeric acid
pentanoic acid, 4-[(6-methoxy-8-quinolinyl)amino]-
pri_275.1391_17.2
8-(3-carboxy-1-methylpropylamino)-6-methoxy-quinoline
DTXSID40891676
4-((6-methoxy-8-quinolinyl)amino)pentanoic acid
SB71032
A846226
carboxy primaquine
CDA22968
mfcd00598907

Excerpt	Reference	Relevance
" In an open-label crossover pharmacokinetic study, 16 healthy volunteers (4 males and 12 females) aged 20 to 47 years were randomized into two groups of three sequential hospital admissions to receive a single oral dose of 30 mg (base) primaquine, 600 mg (base) chloroquine, and the two drugs together."	( Pharmacokinetic interactions between primaquine and chloroquine. Ashley, EA; Charunwatthana, P; Day, NP; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Lawpoolsri, S; Lee, SJ; Pukrittayakamee, S; Tarning, J; White, NJ, 2014)	0.4
" A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs."	( Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Ashley, EA; Blessborn, D; Chairat, K; Day, NP; Hanboonkunupakarn, B; Jittamala, P; Lee, SJ; Nosten, F; Panapipat, S; Pukrittayakamee, S; Tarning, J; Thana, P; White, NJ, 2015)	0.42
" This study was conducted in six healthy adult human volunteers to determine the plasma pharmacokinetic profile of enantiomers of PQ and carboxyprimaquine (cPQ), the major plasma metabolite."	( Enantioselective pharmacokinetics of primaquine in healthy human volunteers. Avula, B; Chaurasiya, ND; ElSohly, MA; Fasinu, PS; Herath, HM; Jain, S; Khan, IA; Khan, SI; McChesney, JD; Nanayakkara, NP; Sahu, R; Stanford, D; Tekwani, BL; Walker, LA; Yates, TW, 2015)	0.42

Excerpt	Relevance	Reference
"Using rats that had been dosed with 20 mg/kg of primaquine diphosphate (11."	( High-performance liquid chromatographic analysis of the metabolism of primaquine and the identification of a new mammalian metabolite. Baker, JK; Clark, AM; Hufford, CD; McChesney, JD, 1982)	0.26
" Higher drug concentrations with repeated dosing were observed for CPMQ, but not for the parent drug, PMQ."	( Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. Chung, WC; Kang, MW; Kim, MY; Kim, SI; Kim, YR; Kim, YS; Kuh, HJ, 2004)	0.32

Class	Description
organonitrogen compound	Any heteroorganic entity containing at least one carbon-nitrogen bond.
organooxygen compound	An organochalcogen compound containing at least one carbon-oxygen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (15.38)	18.7374
1990's	8 (30.77)	18.2507
2000's	2 (7.69)	29.6817
2010's	9 (34.62)	24.3611
2020's	3 (11.54)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (11.54%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	23 (88.46%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.38	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	5.9	2	2	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	9.48	26	3	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
pamaquine pamaquine: structure; RN given refers to parent cpd	1.98	1	0	aminoquinoline
artesunic acid [no description available]	4.41	1	1
pyronaridine [no description available]	4.41	1	1	aminoquinoline
nadp [no description available]	1.98	1	0
quinine [no description available]	1.98	1	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu)	4.41	1	1
mefloquine Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.	1.98	1	0
5-hydroxyprimaquine 5-hydroxyprimaquine: structure given in first source; RN given refers to parent cpd	1.98	1	0	aminoquinoline
maltodextrin maltodextrin : A dextrin in which the D-glucose units are linked by alpha-(1->4) glycosidic bonds.	2.02	1	0

Condition	Relationship Strength	Studies	Trials
Plasmodium vivax Malaria [description not available]	7.71	7	3
Malaria, Vivax Malaria caused by PLASMODIUM VIVAX. This form of malaria is less severe than MALARIA, FALCIPARUM, but there is a higher probability for relapses to occur. Febrile paroxysms often occur every other day.	7.71	7	3
Infections, Plasmodium [description not available]	4.82	2	1
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	4.82	2	1
Plasmodium falciparum Malaria [description not available]	4.72	2	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	4.72	2	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.13	1	0
Deficiency of Glucose-6-Phosphate Dehydrogenase [description not available]	2.13	1	0
Glucosephosphate Dehydrogenase Deficiency A disease-producing enzyme deficiency subject to many variants, some of which cause a deficiency of GLUCOSE-6-PHOSPHATE DEHYDROGENASE activity in erythrocytes, leading to hemolytic anemia.	2.13	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.07	1	0
Acquired Immune Deficiency Syndrome [description not available]	1.98	1	0
Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	1.98	1	0
Acute Disease Disease having a short and relatively severe course.	1.98	1	0
Di Guglielmo Disease [description not available]	1.97	1	0
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	1.97	1	0

8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline

Description

Cross-References

Synonyms (27)

Research Excerpts

Pharmacokinetics

Dosage Studied

Drug Classes (2)

Research

Studies (26)

Market Indicators

Research Demand Index: 11.82

Study Types